<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40824411</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>03</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1875-8312</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>9</Issue><PubDate><Year>2025</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The international journal of cardiovascular imaging</Title><ISOAbbreviation>Int J Cardiovasc Imaging</ISOAbbreviation></Journal><ArticleTitle>Impact of alirocumab on neoatherosclerosis formation and vessel healing after drug-eluting stent implantation in patients with acute myocardial infarction: a substudy of the PACMAN-AMI trial.</ArticleTitle><Pagination><StartPage>1739</StartPage><EndPage>1748</EndPage><MedlinePgn>1739-1748</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10554-025-03472-0</ELocationID><Abstract><AbstractText>Higher on-treatment levels of low-density lipoprotein cholesterol in statin-treated patients were reportedly associated with the occurrence of neoatherosclerosis after drug-eluting stent (DES) implantation. We aimed to investigate the impact of alirocumab added to high-intensity statin therapy on neoatherosclerosis formation among patients with acute myocardial infarction (AMI) treated with DES. This was a pre-specified substudy of the PACMAN-AMI trial, a randomized, double-blind trial comparing alirocumab versus placebo added to high-intensity statin therapy in AMI patients. The present study included patients undergoing optical coherence tomography assessment of DES in the culprit lesion at one year. The frequency of neoatherosclerosis, neointimal thickness, and strut malapposition were compared between treatment groups. Among 191 patients (95 with alirocumab and 96 with placebo), neoatherosclerosis was observed in 13 patients (6.8%) at one year. There was no significant difference in the frequency of neoatherosclerosis between treatment groups (alirocumab 4.2% vs. placebo 9.4%, P&#x2009;=&#x2009;0.25). Among 11 patients with lipid-laden neointima, minimal fibrous cap thickness was greater in the alirocumab group than in the placebo group (217.5&#x2009;&#xb1;&#x2009;122.5 vs. 87.8&#x2009;&#xb1;&#x2009;49.1&#xa0;&#x3bc;m, P&#x2009;=&#x2009;0.02). Neointimal thickness (136.2&#x2009;&#xb1;&#x2009;71.1 vs. 151.4&#x2009;&#xb1;&#x2009;101.4&#xa0;&#x3bc;m, P&#x2009;=&#x2009;0.45) and the frequency of malapposed struts (0.94 vs. 0.53%, P&#x2009;=&#x2009;0.27) were comparable between treatment groups. Among AMI patients treated with DES, there was no significant impact of alirocumab on the frequency of neoatherosclerosis and vessel healing at one year. The observed numerical difference and the finding of more stable neoatheroma in the alirocumab group need further investigation in larger studies with extended follow-up.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kakizaki</LastName><ForeName>Ryota</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ueki</LastName><ForeName>Yasushi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Shinshu University School of Medicine, Nagano, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koskinas</LastName><ForeName>Konstantinos C</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shibutani</LastName><ForeName>Hiroki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine II, Kansai Medical University, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Losdat</LastName><ForeName>Sylvain</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical Research, University of Bern, Bern, Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biccir&#xe8;</LastName><ForeName>Flavio G</ForeName><Initials>FG</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otsuka</LastName><ForeName>Tatsuhiko</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Itabashi Chuo Medical Center, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>H&#xe4;ner</LastName><ForeName>Jonas D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf8;nborg</LastName><ForeName>Jacob</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaiser</LastName><ForeName>Christoph</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiology, University Hospital Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iglesias</LastName><ForeName>Juan F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Geneva University Hospitals, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ondracek</LastName><ForeName>Anna S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spirk</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute of Pharmacology, Bern University Hospital, University of Bern, Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siontis</LastName><ForeName>George C M</ForeName><Initials>GCM</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daemen</LastName><ForeName>Joost</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Engstr&#xf8;m</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lang</LastName><ForeName>Irene M</ForeName><Initials>IM</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>R&#xe4;ber</LastName><ForeName>Lorenz</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland. lorenz.raeber@insel.ch.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Bern University Hospital, Inselspital, University of Bern, Freiburgstrasse 18, Bern, 3010, Switzerland. lorenz.raeber@insel.ch.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Int J Cardiovasc Imaging</MedlineTA><NlmUniqueID>100969716</NlmUniqueID><ISSNLinking>1569-5794</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>PP0SHH6V16</RegistryNumber><NameOfSubstance UI="C571059">alirocumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008078">Cholesterol, LDL</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000924">Anticholesteremic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000091362">PCSK9 Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054855" MajorTopicYN="Y">Drug-Eluting Stents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062645" MajorTopicYN="Y">Percutaneous Coronary Intervention</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D041623" MajorTopicYN="N">Tomography, Optical Coherence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019161" MajorTopicYN="N">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="Y">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003324" MajorTopicYN="Y">Coronary Artery Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058426" MajorTopicYN="N">Neointima</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003331" MajorTopicYN="Y">Coronary Vessels</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058226" MajorTopicYN="N">Plaque, Atherosclerotic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="Y">Myocardial Infarction</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008078" MajorTopicYN="N">Cholesterol, LDL</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014945" MajorTopicYN="Y">Wound Healing</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050171" MajorTopicYN="Y">Dyslipidemias</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000924" MajorTopicYN="Y">Anticholesteremic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000091362" MajorTopicYN="Y">PCSK9 Inhibitors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Low-density lipoprotein cholesterol</Keyword><Keyword MajorTopicYN="N">Neoatherosclerosis</Keyword><Keyword MajorTopicYN="N">Neointimal hyperplasia</Keyword><Keyword MajorTopicYN="N">Proprotein convertase subtilisin/Kexin type 9 inhibitor</Keyword></KeywordList><CoiStatement>Declarations. Conflict of interest: Dr. Kakizaki reported receiving consulting fee from Infraredx USA, speaker fee from Abbott Medical Japan, Boston Scientific Japan, Philips Japan, Orbusneich Medical, manuscript writing fee from Orbusneich Medical and Philips Japan, Support for attending meetings and travel from OM Pharma outside the submitted work. Dr. Ueki reported receiving grants from Astellas Pharma, personal fees from Abbott Vascular, Amgen, Bayer, Daiichi Sankyo, Kowa, NIPRO, and Novartis, outside the submitted work. Dr. Koskinas reported receiving grants from Sanofi, Regeneron, and Infraredx during the conduct of the study and personal fees from Amgen and Daiichi Sankyo outside the submitted work. No other disclosures were reported. Dr. Losdat is employed by the DCR Bern, University of Bern, which has a staff policy of not accepting honoraria or consultancy fees. However, CTU Bern is involved in design, conduct, or analysis of clinical studies funded by not-for-profit and for-profit organizations. In particular, pharmaceutical and medical device companies provide direct funding to some of these studies. (for an up-to-date list of DCR Bern&#x2019;s conflicts of interest, see https://dcr.unibe.ch/services/terms__conditions/index_eng.html ) Dr. Biccir&#xe8; reported receiving consulting fee from Abbott, speaker fee from Abbott, Ultragenyx, and Sanofi outside the submitted work. Dr. Otsuka reported receiving speaker fees from Amgen, Nipro, and Kowa. Dr. L&#xf8;nborg reported receiving grants from Boston Scientific, consulting fees from Boston Scientific, speakers fee from Abbott and Boston Scientific, and Support for attending meetings and travel from Abbott, and owns stock in Novo Nordisk. Dr. Kaiser reported receiving consulting fees from Unimedtec Switzerland and Swiss office of federal health. Dr. Iglesias reported receiving grants from Biotronik, Concept Medical, and Terumo, consulting fees from Medtronic, Biotronik, Cordis, and ReCor Medical, speakers fees from Medtronic, Penumbra, Biotronik, Concept Medical, BRISTOL MYERS SQUIBB/PFIZER, Cordis, and Recor Medical, Support for attending meetings and travel from Biotronik, and participating Data Safety Monitoring Board of the CoSTAR trial (NCT04870424). Dr. Spirk reported receiving personal fees from Sanofi-Aventis (Switzerland) at the time of study conduct and Cook Medical outside the submitted work. Dr. Daemen reported receiving institutional grant/research support from Abbott Vascular, Boston Scientific, ACIST Medical, Medtronic, Pie Medical, and ReCor medical, and consultancy and speaker fees from Abbott Vascular, Abiomed, ACIST medical, Boston Scientific, Cardialysis BV, CardiacBooster, Kaminari Medical, ReCor Medical, PulseCath, Pie Medical, Sanofi, Siemens Health Care and Medtronic. Dr Engstr&#xf8;m reported advisory board fees from Abbott and Novo Nordisk and speaker fees from Boston Scientific outside the submitted work. Dr. Lang has relationships with drug companies including AOP-Health, Actelion-Janssen, MSD, United Therapeutics, Pulnovo, Medtronic, INARI, Neutrolis and Sanofi. In addition to being investigator in trials involving these companies, relationships include consultancy service, research grants, and membership of scientific advisory boards. Dr. R&#xe4;ber reported receiving grants from Sanofi, Regeneron, and Infraredx to Inselspital and speaker fees from Sanofi during the conduct of the study and grants from Abbott, Heartflow, Boston Scientific, and Biotronik to Inselspital and grants from Abbott, Amgen, AstraZeneca, Occlutech, Sanofi, Canon, and Medtronic for speaker and consultation fees outside the submitted work. Ethical approval: This study was performed in line with the principles of the Declaration of Helsinki, and the study was approved by the ethical committee at each site. Consent to participate: Informed consent was obtained from all individual participants included in the study, all patients provided written informed consent. Consent to publish: All participants provided informed consent, acknowledging that their health-related and personal information (and samples) would be shared only in encrypted form for research purposes, including international collaboration, and that their names would not be published in any form.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>3</Day><Hour>18</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>18</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>18</Day><Hour>11</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40824411</ArticleId><ArticleId IdType="pmc">PMC12405363</ArticleId><ArticleId IdType="doi">10.1007/s10554-025-03472-0</ArticleId><ArticleId IdType="pii">10.1007/s10554-025-03472-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Piccolo R, Bonaa KH, Efthimiou O, Varenne O, Baldo A et al (2019) Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials. Lancet Jun 22(10190):2503&#x2013;2510. 10.1016/S0140-6736(19)30474-X</Citation><ArticleIdList><ArticleId IdType="pubmed">31056295</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JM, Park KW, Han JK, Yang HM, Kang HJ et al (2014) Three-year patient-related and stent-related outcomes of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice (from the multicenter prospective EXCELLENT and RESOLUTE-Korea Registries). Am J Cardiol Nov 1(9):1329&#x2013;1338. 10.1016/j.amjcard.2014.07.065</Citation><ArticleIdList><ArticleId IdType="pubmed">25217457</ArticleId></ArticleIdList></Reference><Reference><Citation>Camenzind E, Wijns W, Mauri L, Kurowski V, Parikh K et al (2012) Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial. Lancet Oct 20(9851):1396&#x2013;1405. 10.1016/S0140-6736(12)61336-1</Citation><ArticleIdList><ArticleId IdType="pubmed">22951082</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanchin C, Ueki Y, Zanchin T, Haner J, Otsuka T et al (2019) Everolimus-Eluting biodegradable polymer versus Everolimus-Eluting durable polymer stent for coronary revascularization in routine clinical practice. JACC Cardiovasc Interv Sep 9(17):1665&#x2013;1675. 10.1016/j.jcin.2019.04.046</Citation><ArticleIdList><ArticleId IdType="pubmed">31422088</ArticleId></ArticleIdList></Reference><Reference><Citation>Takano M, Yamamoto M, Inami S, Murakami D, Ohba T et al (2009) Appearance of lipid-laden intima and neovascularization after implantation of bare-metal stents extended late-phase observation by intracoronary optical coherence tomography. J Am Coll Cardiol Dec 29(1):26&#x2013;32. 10.1016/j.jacc.2009.08.032</Citation><ArticleIdList><ArticleId IdType="pubmed">20117359</ArticleId></ArticleIdList></Reference><Reference><Citation>Taniwaki M, Radu MD, Zaugg S, Amabile N, Garcia-Garcia HM et al (2016) Mechanisms of very late Drug-Eluting stent thrombosis assessed by optical coherence tomography. Circulation Feb 16(7):650&#x2013;660. 10.1161/CIRCULATIONAHA.115.019071</Citation><ArticleIdList><ArticleId IdType="pubmed">26762519</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura D, Attizzani GF, Toma C, Sheth T, Wang W et al (2016) Failure mechanisms and neoatherosclerosis patterns in very late Drug-Eluting and Bare-Metal stent thrombosis. Circ Cardiovasc Interv Sep 9(9). 10.1161/CIRCINTERVENTIONS.116.003785</Citation><ArticleIdList><ArticleId IdType="pubmed">27582113</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawai K, Virmani R, Finn AV (2022) In-Stent restenosis. Interv Cardiol Clin Oct 11(4):429&#x2013;443. 10.1016/j.iccl.2022.02.005</Citation><ArticleIdList><ArticleId IdType="pubmed">36243488</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakazawa G, Finn AV, Joner M, Ladich E, Kutys R et al (2008) Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation Sep 9(11):1138&#x2013;1145. 10.1161/CIRCULATIONAHA.107.762047</Citation><ArticleIdList><ArticleId IdType="pubmed">18725485</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuroda M, Otake H, Shinke T, Takaya T, Nakagawa M et al (2016) The impact of in-stent neoatherosclerosis on long-term clinical outcomes: an observational study from the Kobe University Hospital optical coherence tomography registry. <i>EuroIntervention</i>. Dec 10.;12(11):e1366-e1374. 10.4244/EIJY15M12_05</Citation><ArticleIdList><ArticleId IdType="pubmed">26690315</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z, Matsumura M, Mintz GS, Noguchi M, Fujimura T et al (2022) Prevalence and impact of neoatherosclerosis on clinical outcomes after percutaneous treatment of Second-Generation Drug-Eluting stent restenosis. Circ Cardiovasc Interv Sep 15(9):e011693. 10.1161/CIRCINTERVENTIONS.121.011693</Citation><ArticleIdList><ArticleId IdType="pubmed">36126137</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimono H, Kajiya T, Takaoka J, Miyamura A, Inoue T et al (2021) Characteristics of recurrent in-stent restenosis after second- and third-generation drug-eluting stent implantation. Coron Artery Dis Jan 32(1):36&#x2013;41. 10.1097/MCA.0000000000000945</Citation><ArticleIdList><ArticleId IdType="pubmed">32826448</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA et al (2018) Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med Nov 29(22):2097&#x2013;2107. 10.1056/NEJMoa1801174</Citation><ArticleIdList><ArticleId IdType="pubmed">30403574</ArticleId></ArticleIdList></Reference><Reference><Citation>Raber L, Ueki Y, Otsuka T, Losdat S, Haner JD et al (2022) Effect of Alirocumab added to High-Intensity Statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial. JAMA May 10(18):1771&#x2013;1781. 10.1001/jama.2022.5218</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8978048</ArticleId><ArticleId IdType="pubmed">35368058</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanchin C, Koskinas KC, Ueki Y, Losdat S, Haner JD et al (2021) Effects of the PCSK9 antibody Alirocumab on coronary atherosclerosis in patients with acute myocardial infarction: a serial, multivessel, intravascular ultrasound, near-infrared spectroscopy and optical coherence tomography imaging study-Rationale and design of the PACMAN-AMI trial. Am Heart J Aug 238:33&#x2013;44. 10.1016/j.ahj.2021.04.006</Citation><ArticleIdList><ArticleId IdType="pubmed">33951415</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C et al (2023) 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J Oct 12(38):3720&#x2013;3826. 10.1093/eurheartj/ehad191</Citation><ArticleIdList><ArticleId IdType="pubmed">37622654</ArticleId></ArticleIdList></Reference><Reference><Citation>Guagliumi G, Shimamura K, Sirbu V, Garbo R, Boccuzzi G et al (2018) Temporal course of vascular healing and neoatherosclerosis after implantation of durable- or biodegradable-polymer drug-eluting stents. Eur Heart J Jul 7(26):2448&#x2013;2456. 10.1093/eurheartj/ehy273</Citation><ArticleIdList><ArticleId IdType="pubmed">29788263</ArticleId></ArticleIdList></Reference><Reference><Citation>Tearney GJ, Regar E, Akasaka T, Adriaenssens T, Barlis P et al (2012) Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the international working group for intravascular optical coherence tomography standardization and validation. J Am Coll Cardiol Mar 20(12):1058&#x2013;1072. 10.1016/j.jacc.2011.09.079</Citation><ArticleIdList><ArticleId IdType="pubmed">22421299</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoshino M, Yonetsu T, Kanaji Y, Usui E, Yamaguchi M et al (2019) Impact of baseline plaque characteristic on the development of neoatherosclerosis in the very late phase after stenting. J Cardiol Jul 74(1):67&#x2013;73. 10.1016/j.jjcc.2019.01.002</Citation><ArticleIdList><ArticleId IdType="pubmed">30733110</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagano Y, Otake H, Toba T, Kuroda K, Shinkura Y et al (2019) Impaired Cholesterol-Uptake capacity of HDL might promote Target-Lesion revascularization by inducing neoatherosclerosis after stent implantation. J Am Heart Assoc May 7(9):e011975. 10.1161/JAHA.119.011975</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6512103</ArticleId><ArticleId IdType="pubmed">30995875</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakizaki R, H&#xe4;ner J, Taniwaki M, Ohno Y, Yahagi K, THE IMPACT OF ACHIEVING GUIDELINE-ENDORSED LDL CHOLESTEROL LEVELS ON NEOATHEROSCLEROSIS FORMATION IN PATIENTS WITH STEMI (2025) : A SUBSTUDY OF THE RANDOMIZED CONNECT TRIAL. Presented at: American Control Conference 74th Annual Scientific Session; March ; Chicago, IL</Citation></Reference><Reference><Citation>Niccoli G, Dato I, Imaeva AE, Antonazzo Panico R, Roberto M et al (2014) Association between inflammatory biomarkers and in-stent restenosis tissue features: an optical coherence tomography study. Eur Heart J Cardiovasc Imaging Aug 15(8):917&#x2013;925. 10.1093/ehjci/jeu035</Citation><ArticleIdList><ArticleId IdType="pubmed">24618655</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao YX, Li S, Liu HH, Li JJ (2018) Impact of PCSK9 monoclonal antibodies on Circulating hs-CRP levels: a systematic review and meta-analysis of randomised controlled trials. BMJ Open Oct 4(9):e022348. 10.1136/bmjopen-2018-022348</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6173233</ArticleId><ArticleId IdType="pubmed">30287608</ArticleId></ArticleIdList></Reference><Reference><Citation>Taniwaki M, Windecker S, Zaugg S, Stefanini GG, Baumgartner S et al (2015) The association between in-stent neoatherosclerosis and native coronary artery disease progression: a long-term angiographic and optical coherence tomography cohort study. Eur Heart J Aug 21(32):2167&#x2013;2176. 10.1093/eurheartj/ehv227</Citation><ArticleIdList><ArticleId IdType="pubmed">26040806</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakai R, Sekimoto T, Koba S, Mori H, Matsukawa N et al (2023) Impact of triglyceride-rich lipoproteins on early in-stent neoatherosclerosis formation in patients undergoing Statin treatment. J Clin Lipidol Mar-Apr 17(2):281&#x2013;290. 10.1016/j.jacl.2023.01.004</Citation><ArticleIdList><ArticleId IdType="pubmed">36828767</ArticleId></ArticleIdList></Reference><Reference><Citation>Taniwaki M, Haner JD, Kakizaki R, Ohno Y, Yahagi K et al (2024) Long-term effect of biodegradable vs durable polymer everolimus-eluting stents on neoatherosclerosis in ST-segment elevation myocardial infarction: the CONNECT trial. Eur Heart J Sep 1. 10.1093/eurheartj/ehae589</Citation><ArticleIdList><ArticleId IdType="pubmed">39217617</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang JY, Kim JS, Shin DH, Kim BK, Ko YG et al (2015) Favorable effect of optimal lipid-lowering therapy on neointimal tissue characteristics after drug-eluting stent implantation: qualitative optical coherence tomographic analysis. Atherosclerosis Oct 242(2):553&#x2013;559. 10.1016/j.atherosclerosis.2015.08.014</Citation><ArticleIdList><ArticleId IdType="pubmed">26318104</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura D, Dohi T, Ishihara T, Kikuchi A, Mori N et al (2021) Predictors and outcomes of neoatherosclerosis in patients with in-stent restenosis. EuroIntervention Aug 27(6):489&#x2013;496. 10.4244/EIJ-D-20-00539</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9725017</ArticleId><ArticleId IdType="pubmed">32985411</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan X, Han Y, Hu X, Jiang M, Feng H et al (2023) Lipoprotein (a) is related to In-Stent neoatherosclerosis incidence rate and plaque vulnerability: optical coherence tomography study. Int J Cardiovasc Imaging Feb 39(2):275&#x2013;284. 10.1007/s10554-022-02736-3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9870965</ArticleId><ArticleId IdType="pubmed">36315364</ArticleId></ArticleIdList></Reference><Reference><Citation>Furtado RHM, Fagundes AA Jr., Oyama K, Zelniker TA, Tang M et al (2022) Effect of Evolocumab in patients with prior percutaneous coronary intervention. Circ Cardiovasc Interv Mar 15(3):e011382. 10.1161/CIRCINTERVENTIONS.121.011382</Citation><ArticleIdList><ArticleId IdType="pubmed">35209731</ArticleId></ArticleIdList></Reference><Reference><Citation>Yonetsu T, Kim JS, Kato K, Kim SJ, Xing L et al (2012) Comparison of incidence and time course of neoatherosclerosis between bare metal stents and drug-eluting stents using optical coherence tomography. Am J Cardiol Oct 1(7):933&#x2013;939. 10.1016/j.amjcard.2012.05.027</Citation><ArticleIdList><ArticleId IdType="pubmed">22727183</ArticleId></ArticleIdList></Reference><Reference><Citation>Song L, Mintz GS, Yin D, Yamamoto MH, Chin CY et al (2017) Neoatherosclerosis assessed with optical coherence tomography in restenotic bare metal and first- and second-generation drug-eluting stents. Int J Cardiovasc Imaging Aug 33(8):1115&#x2013;1124. 10.1007/s10554-017-1106-2</Citation><ArticleIdList><ArticleId IdType="pubmed">28281026</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SY, Hur SH, Lee SG, Kim SW, Shin DH et al (2015) Optical coherence tomographic observation of in-stent neoatherosclerosis in lesions with more than 50% neointimal area stenosis after second-generation drug-eluting stent implantation. Circ Cardiovasc Interv Feb 8(2):e001878. 10.1161/CIRCINTERVENTIONS.114.001878</Citation><ArticleIdList><ArticleId IdType="pubmed">25613674</ArticleId></ArticleIdList></Reference><Reference><Citation>Jinnouchi H, Otsuka F, Sato Y, Bhoite RR, Sakamoto A et al (2020) Healthy strut coverage after coronary stent implantation: an ex vivo human autopsy study. Circ Cardiovasc Interv May 13(5):e008869. 10.1161/CIRCINTERVENTIONS.119.008869</Citation><ArticleIdList><ArticleId IdType="pubmed">32338525</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>